Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30155506 | 0.82 | MEN1 (0.42) | KMT2AMEN1HTTL3MBTL1RAB9A | |
| SCHEMBL18038595 | 0.77 | KMT2A (0.54) | RIPK1KMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL8773482 | 0.75 | MEN1 (0.69) | RIPK1KMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL27885169 | 0.72 | MEN1 (0.49) | RIPK1KMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL30912906 | 0.72 | KMT2A (0.49) | RIPK1KMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL22035000 | 0.71 | HDAC1 (0.47) | RIPK1KMT2AMEN1L3MBTL1RAB9A | |
| SCHEMBL567235 | 0.70 | KMT2A (0.54) | RIPK1KMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL343793 | 0.70 | KMT2A (0.50) | RIPK1KMT2AMEN1RAB9AALDH1A1 | |
| SCHEMBL22982786 | 0.70 | NPC1 (0.50) | RIPK1KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL17275348 | 0.70 | NPC1 (0.50) | KMT2AMEN1L3MBTL1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7915271-B2 | 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | CETP, MTTP, APOB | RIPK1 2820/4885KMT2A 2516/4885MEN1 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.